WESTLAKE VILLAGE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company that focuses on the development and commercialization of medicines for unmet needs in immunodeficiency dermatological diseases and called conditions, or immuno-dermatology, today has been selected for inclusion in the NASDAQ Biotechnology Register (Nasdaq: NBI), based on the results of the annual rework of the index announced by Nasdaq on 11 December 2020. introducing effective growth before the U.S. market opens on Monday, December 21, 2020.
The NASDAQ Biotechnology Index is designed to monitor the performance of a set of securities listed on the NASDAQ Stock Market that are classified as biotechnology or pharmaceutical companies, and is a weight index. modified capital. According to NASDAQ, the NBI is reconfigured annually in December according to a set of eligibility criteria including minimum market capitalization and average daily trading volume. The index currently has 198 secure parts. For more information about the NBI, visit https://indexes.nasdaqomx.com/index/overview/nbi.
About Arcutis – Biology, applied to the skin.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company that focuses on developing and trading medicines for unmet needs in diseases and dermatological conditions with a protective medium, or immuno-dermatology. The company is reducing recent advances in immunology and inflammation to develop different therapies against biologically proven targets to solve ongoing treatment challenges in severe skin diseases. Arcutis ’strong pipeline includes four novel drug candidates currently under development for a range of inflammatory dermatological conditions. The company’s leading product candidate, contemporary roflumilast, has the potential to restore the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit www.arcutis.com or follow the company on LinkedIn and Twitter.
Investors and Media:
Heather Rowe Armstrong
Vice President, Investor Relations & Corporate Communications
[email protected]
805-418-5006, Ext. 740